# A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors

Source: https://onco.cc/trials/nct04396821/  
OnCo record `nct04396821` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FOLFOX, Gemcitabine in metastatic cancer, run by Transcenta Therapeutics (Hangzhou) Co., Ltd., active and no longer recruiting.

## Summary

A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors is a phase 1/2 interventional study registered as NCT04396821 by Transcenta Therapeutics (Hangzhou) Co., Ltd., with 150 participants planned, started 2020-05-28 and due to reach its primary completion in 2026-05-30. Interventions recorded: TST001, Nivolumab Injection [Opdivo], mFOLFOX6, Gemcitabine, Albumin-Bound Paclitaxel. Conditions listed: Advanced Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Pancreatic Cancer. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04396821
- Phase: 1/2
- Setting: A Phase I/IIa Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of TST001 Administered as Monotherapy or in Combination With Nivolumab or Standard of Care in Patients With Locally Advanced or Metastatic Solid Tumors
- Sponsor: Transcenta Therapeutics (Hangzhou) Co., Ltd.
- Enrolled: 150

## Sources

- ClinicalTrials.gov NCT04396821: https://clinicaltrials.gov/study/NCT04396821

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- drugs: [FOLFOX (5-FU, leucovorin, oxaliplatin)](https://onco.cc/drugs/folfox/), [Gemcitabine](https://onco.cc/drugs/gemcitabine/), [TST001](https://onco.cc/drugs/tst001/)

---
JSON: https://onco.cc/api/v1/entities/nct04396821.json